Modeling the Functional State of the Reverse Transcriptase of Hepatitis B Virus and Its Application to Probing Drug-protein Interaction

Overview

Journal BMC Bioinformatics

Publisher Biomed Central

Specialty Biology

Date 2016 Sep 3

PMID 27587008

Citations 6

Authors

Xiaojun Xu

Hong Thai

Kathryn M Kitrinos

Guoliang Xia

Anuj Gaggar

Matthew Paulson

Lilia Ganova-Raeva

Yury Khudyakov

James Lara

Affiliations

Soon will be listed here.

Abstract

Background: Herein, the predicted atomic structures of five representative sequence variants of the reverse transcriptase protein (RT) of hepatitis B virus (HBV), sampled from patients with rapid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been examined to identify structural variations between them in order to assess structural and functional properties of HBV-RT variants associated with the differential responses to TDF treatment.

Results: We utilized a hybrid computational approach to model the atomistic structures of HBV-RT/DNA-RNA/dATP and HBV-RT/DNA-RNA/TFV-DP (tenofovir diphosphate) complexes with the native hybrid DNA-RNA substrate in place. Multi-nanosecond molecular dynamics (MD) simulations of HBV-RT/DNA-RNA/dATP complexes revealed strong coupling of the natural nucleotide substrate, dATP, to the active site of the RT, and the differential involvement of the two putative magnesium cations (Mg(2+)) at the active site, whereby one Mg(2+) directly bridges the interaction between dATP and HBV-RT and the other serves as a coordinator to maintain an optimal configuration of the active site. Solvated interaction energy (SIE) calculated in MD simulations of HBV-RT/DNA-RNA/TFV-DP complexes indicate no differential binding affinity between TFV-DP and HBV-RT variants identified in patients with slow or rapid response to TDF treatment.

Conclusion: The predicted atomic structures accurately represent functional states of HBV-RT. The equivalent interaction between TFV-DP and each examined HBV-RT variants suggests that binding affinity of TFV-DP to HBV-RT is not associated with delayed viral clearance.

Citing Articles

Small Molecule Drugs Targeting Viral Polymerases.

Palazzotti D, Sguilla M, Manfroni G, Cecchetti V, Astolfi A, Letizia Barreca M Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794231 PMC: 11124969. DOI: 10.3390/ph17050661.

Virtual Screening of Hepatitis B Virus Pre-Genomic RNA as a Novel Therapeutic Target.

Olenginski L, Kasprzak W, Attionu S, Shapiro B, Dayie T Molecules. 2023; 28(4).

PMID: 36838792 PMC: 9963113. DOI: 10.3390/molecules28041803.

Predicted structure of the hepatitis B virus polymerase reveals an ancient conserved protein fold.

Tajwar R, Bradley D, Ponzar N, Tavis J Protein Sci. 2022; 31(10):e4421.

PMID: 36173165 PMC: 9601786. DOI: 10.1002/pro.4421.

Complex genetic encoding of the hepatitis B virus on-drug persistence.

Thai H, Lara J, Xu X, Kitrinos K, Gaggar A, Chan H Sci Rep. 2020; 10(1):15574.

PMID: 32968103 PMC: 7511938. DOI: 10.1038/s41598-020-72467-9.

Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus.

Teppa E, Nadalin F, Combet C, Zea D, David L, Carbone A Virus Evol. 2020; 6(1):veaa006.

PMID: 32158552 PMC: 7050494. DOI: 10.1093/ve/veaa006.

References

Durand-Gasselin L, Van Rompay K, Vela J, Henne I, Lee W, Rhodes G . Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm. 2009; 6(4):1145-51. PMC: 2777719. DOI: 10.1021/mp900036s. View

Menendez-Arias L, Alvarez M, Pacheco B . Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance. Curr Opin Virol. 2014; 8:1-9. DOI: 10.1016/j.coviro.2014.04.005. View

Miller M, Margot N, Hertogs K, Larder B, Miller V . Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids. 2001; 20(4-7):1025-8. DOI: 10.1081/NCN-100002483. View

Wang J, Wang W, Kollman P, Case D . Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model. 2006; 25(2):247-60. DOI: 10.1016/j.jmgm.2005.12.005. View

Coppolino G, Simeoni M, Summaria C, Postorino M, Rivoli L, Strazzulla A . The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol. 2015; 28(4):393-402. DOI: 10.1007/s40620-015-0214-0. View

Das K, Xiong X, Yang H, Westland C, Gibbs C, Sarafianos S . Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol. 2001; 75(10):4771-9. PMC: 114232. DOI: 10.1128/JVI.75.10.4771-4779.2001. View

Sulea T, Cui Q, Purisima E . Solvated interaction energy (SIE) for scoring protein-ligand binding affinities. 2. Benchmark in the CSAR-2010 scoring exercise. J Chem Inf Model. 2011; 51(9):2066-81. DOI: 10.1021/ci2000242. View

Vriend G . WHAT IF: a molecular modeling and drug design program. J Mol Graph. 1990; 8(1):52-6, 29. DOI: 10.1016/0263-7855(90)80070-v. View

Michailidis E, Kirby K, Hachiya A, Yoo W, Hong S, Kim S . Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012; 44(7):1060-71. PMC: 3522522. DOI: 10.1016/j.biocel.2012.04.006. View

10.

Zhang Y . I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008; 9:40. PMC: 2245901. DOI: 10.1186/1471-2105-9-40. View

11.

Aqvist J, Medina C, Samuelsson J . A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 1994; 7(3):385-91. DOI: 10.1093/protein/7.3.385. View

12.

Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C . Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins. 2006; 65(3):712-25. PMC: 4805110. DOI: 10.1002/prot.21123. View

13.

Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

14.

Robbins B, Srinivas R, Kim C, Bischofberger N, Fridland A . Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998; 42(3):612-7. PMC: 105507. DOI: 10.1128/AAC.42.3.612. View

15.

Eldar A, Elowitz M . Functional roles for noise in genetic circuits. Nature. 2010; 467(7312):167-73. PMC: 4100692. DOI: 10.1038/nature09326. View

16.

Marcellin P, Asselah T . Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013; 28(6):912-23. DOI: 10.1111/jgh.12213. View

17.

Webb B, Sali A . Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinformatics. 2014; 47:5.6.1-32. DOI: 10.1002/0471250953.bi0506s47. View

18.

Xu D, Jaroszewski L, Li Z, Godzik A . AIDA: ab initio domain assembly server. Nucleic Acids Res. 2014; 42(Web Server issue):W308-13. PMC: 4086082. DOI: 10.1093/nar/gku369. View

19.

Perry C, Simpson D . Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs. 2009; 69(16):2245-56. DOI: 10.2165/10482940-000000000-00000. View

20.

Hachiya A, Kodama E, Schuckmann M, Kirby K, Michailidis E, Sakagami Y . K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One. 2011; 6(1):e16242. PMC: 3020970. DOI: 10.1371/journal.pone.0016242. View